|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 1777-1786
RAPID COMMUNICATION
Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilitates Scoring and Selection of Transduced Progenitors In Vitro and Identification of Genetically Modified Cells In Vivo
By
Derek A. Persons,
James A. Allay,
Esther R. Allay,
Richard J. Smeyne,
Richard A. Ashmun,
Brian P. Sorrentino, and
Arthur W. Nienhuis
From the Division of Experimental Hematology, the Department of Hematology/Oncology, the Department of Developmental Neurobiology, and the Department of Experimental Oncology, St Jude Children's Research Hospital, Memphis, TN.
 |
ABSTRACT |
We have investigated the utility of the green fluorescent protein (GFP) to serve as a marker to assess retroviral gene transfer into hematopoietic cells and as a tool to identify and enrich for cells expressing high levels of the vector-encoded transcript. GFP, by virtue of a naturally occurring chromophore encoded in its primary sequence, displays autonomous fluorescence, thus eliminating the need for antibody or cytochemical staining to detect its expression. A bicistronic murine stem cell virus (MSCV)-based retroviral vector was constructed containing the GFP cDNA and a mutant, human dihydrofolate reductase gene. High-titer, ecotropic retroviral producer cells free of replication competent virus were generated and used to transduce murine bone marrow cells by cocultivation. Within 24 hours after completion of the transduction procedure, a high proportion (40% to 70%) of the marrow cells were intensely fluorescent compared to mock-transduced cells or cells transduced with a control retrovirus. Erythroid and myeloid hematopoietic colonies derived from GFP-transduced marrow were easily scored for retroviral gene transfer by direct in situ fluorescence microscopy. Clonogenic progenitors expressing increased levels of antifolate drug resistance could be enriched from the GFP-transduced marrow population by fluorescence activated cell sorting of cells expressing high levels of GFP. In vivo, splenic hematopoietic colonies and peripheral blood cells from animals transplanted with GFP-transduced marrow displayed intense fluorescence. These results show that GFP is an excellent marker for scoring and tracking gene-modified hematopoietic cells and for allowing rapid selection and enrichment of transduced cells expressing high levels of the transgene.
| |
INTRODUCTION |
THE POTENTIAL use of recombinant retroviral vectors as gene transfer vehicles for delivery of therapeutic genes to primitive hematopoietic cells continues to hold promise for the treatment of many inherited, single-gene disorders such as sickle cell anemia, the thalassemias, and the immunodeficiency syndromes.1-5 In addition, various genetic therapy strategies that rely on gene transfer into stem cells are under development for the treatment of acquired immunodeficiency syndrome and cancer.6,7 Although high levels of retroviral gene transfer into murine primitive hematopoietic progenitors are now routinely achieved,8,9 efficient gene transfer into long-term repopulating hematopoietic cells of larger animals, including humans, has been problematic.10-12 One strategy that may help overcome these problems is the inclusion of a selectable marker gene in retroviral vectors to allow identification, enumeration, and enrichment of transduced cells.
Genes encoding resistance to toxic drugs such as neomycin,13 puromycin,14 and hygromycin15 have been widely used in retroviral vectors to aid in the identification of transduced cells in vitro. However, this approach is limited by the potential for nonspecific drug toxicity and the inability to easily measure transgene expression levels. In addition, the use of drug-resistance genes to facilitate enrichment of transduced hematopoietic cells before transplantation has not been generally used for a variety of reasons, including the necessity for prolonged culture periods to obtain a differential selection of transduced versus nontransduced cells. Alternatively, cytochemical markers such as  -galactosidase16 and alkaline phosphatase17 have been investigated as marker genes but are also somewhat problematic because of their endogenous expression in some cell types,18 the requirement to transport flourogenic substrates across the cell membrane for detection,19 and the potential for passive transfer to nontransduced cells.
Recently, several groups have begun to use a variety of cell-surface markers, including the multidrug resistance protein,20 the low-affinity nerve growth factor receptor,21 CD24 antigen,22 and the murine heat-stable antigen,23 to identify transduced cells by immunofluorescent antibody staining techniques. With this approach, transduced cells and their subpopulations can be enumerated, characterized, and enriched without drug toxicity using multiparameter flow cytometry. Using CD24 as a marker of gene transfer, Pawliuk et al22 were able to identify and enrich for transduced murine hematopoietic cells. Both spleen colony-forming cells and peripheral blood (PB) cells in mice transplanted with virally transduced, CD24-enriched hematopoietic precursors had a higher level of CD24 positivity compared to animals transplanted with unsorted cells.
One of the most promising, new markers currently being used to investigate gene transfer is the green fluorescent protein (GFP). Cloned from the jellyfish Aequorea victoria,24 the GFP gene encodes a 238-amino acid polypeptide containing a naturally occurring chromophore consisting of an imidazolone ring formed by the autocyclization of amino acid residues serine-65, tyrosine-66, and glycine-67.25 Various codon usage changes and point mutations in the wild-type GFP gene have led to several versions of GFP with improved fluorescence intensity in mammalian cells.26,27 Because fluorescence from GFP requires no substrates, cofactors, or additional gene products, cells expressing GFP can be easily scored in real-time by flow cytometry or fluorescence microscopy without cell manipulation.28 GFP has been readily detected in the living tissues of mice with a GFP-encoding transgene.29 Recently, both adenoviral26 and retroviral vectors30,31 containing a GFP cassette have been used to evaluate gene transfer into human endothelial cells, human tumor cell lines, and murine fibroblasts. This led us to evaluate the ability of GFP to act as a marker for retroviral gene transfer into hematopoietic progenitor cells.
In this study, we report the ability to achieve high-level gene transfer and expression of GFP in murine bone marrow (BM) as assessed by flow cytometry, in clonal hematopoietic colonies as evaluated by fluorescence microscopy, in hematopoietic progenitors as reflected by enrichment of transduced cells after cell sorting, and in progenitor-derived spleen colonies and PB cells of all lineages in vivo. GFP appears to be an excellent marker for evaluating gene transfer and for isolating, enriching, and tracking genetically marked cells.
| |
MATERIALS AND METHODS |
Cell lines and vector construction.
The ecotropic packaging cell line GP + E8632 was used for the generation of helper-free recombinant retroviruses. JZenCD24tkNEO viral producer cells22 (CD24 producer cells) were a generous gift of R.K. Humphries (Terry Fox Laboratory, Vancouver, British Columbia, Canada). GP + E86, CD24 producer cells, 293T,33 and NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mmol/L glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a 5% CO2, humidified atmosphere.
The neomycin coding cassette in MSCVNEO2.134 (kindly provided by R. Hawley, Sunnybrook Research Institute, Toronto, Ontario, Canada) was replaced with a DNA fragment containing an internal ribosome entry site (ir) from the encephalomyocarditis virus35 linked to a gene encoding a human dihydrofolate reductase variant containing a leucine to tyrosine substitution in codon 22 (termed L22Y). When expressed in murine myeloid progenitors, the L22Y gene confers to cells a 100-fold increase in trimetrexate (TMTX) resistance.36 The GFP gene from the EGFP-1 plasmid (Clontech Laboratories, Palo Alto, CA) was cloned into the resulting plasmid MirL22Y to generate the bicistronic vector MGirL22Y (Fig 1B) using standard methodology.
View larger version (39K):
[in this window]
[in a new window]
| Fig 1.
(A) Southern blot analysis to assess proviral integrity and copy number in cells genetically modified with the MGirL22Y retroviral vector. Genomic DNA from cells was restricted with Asc I which cuts once within each viral LTR, liberating the full-length, 3.6-kb retroviral genome. DNAs analyzed (15 µg) in each lane are: 1, GP + E86 DNA containing 50 pg of the MGirL22Y vector plasmid DNA; 2, GP + E86; 3, GP + E86-derived MGirL22Y viral producer; 4, NIH 3T3; 5, GFP vector-transduced NIH 3T3; 6, CD24 vector-transduced BM; 7, GFP vector-transduced BM. The migration patterns of the molecular-weight markers are shown at left. (B) Schematic of the MGirL22Y retroviral vector which consists of the MSCV retroviral backbone containing the coding sequence of GFP followed by an internal ribosomal entry site (IRES or ir) from the encephalomyocarditis virus linked to a mutant dihydrofolate reductase gene (L22Y). The designated probe region depicts the fragment used in the Southern analysis.
|
|
Generation of high-titer, ecotropic MGirL22Y virus producer cells.
Conditioned media containing high-titer, amphotropic MGirL22Y vector particles was derived by cotransfection of 293T cells with the plasmid containing the MGirL22Y sequences and a helper plasmid containing the required gag, pol, and env retroviral genes driven by a Moloney leukemia virus LTR (D. Persons and E. Vanin, manuscript in preparation). This media was used to transduce GP + E86 cells a total of six times over 3 days. The cells were then allowed to recover for 24 hours and subsequently the media was changed to contain 10% thymidine phosphorylase-treated, heat-inactivated FCS and 100 nmol/L trimetrexate. After 7 days in culture, all cells on control plates were killed and the polyclonal trimetrexate-resistant population of vector-transduced cells was analyzed for GFP expression by flow cytometry. The highest expressing 10% of cells were sterilely sorted and subsequently expanded. The resulting viral titer of conditioned media from this producer population was 5 × 106 trimetrexate-resistant colony-forming units per milliter as assayed using NIH 3T3 cells. These virus-producing cells were free of replication competent retrovirus as demonstrated by the failure of trimetrexate resistance to be transferred from virally transduced NIH 3T3 cells to naive NIH 3T3 cells. Specifically, 10 mL of conditioned media from the GFP producer cells was used to transduce 105 NIH 3T3 cells which were then passaged in culture for 3 weeks without selection. Ten milliliters of conditioned media from these cells was then used to transduce 105 naive NIH 3T3 cells, and 48 hours later selection was applied with 100 nmol/L trimetrexate in DMEM supplemented with 10% thymidine phosphorylase-treated, heat-inactivated FCS. No trimetrexate resistant colonies were observed.
DNA analysis.
Genomic DNA from the MGirL22Y producer cells, transduced NIH 3T3 cells, and transduced murine BM was purified using the Pure Gene DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's specifications. Southern blot analysis of restricted DNA was performed by standard methods.37 Densitometric quantitation was performed using a PhosphoImager 425F (Molecular Dynamics, Sunnyvale, CA) and ImageQuant software.
Retroviral transduction of BM cells.
Retroviral transduction of murine BM cells was performed as previously described.38 Briefly, BM was harvested from 8- to 12-week-old female C57/B16 mice 2 days after treatment with 150 mg/kg 5-fluoruracil (5-FU; Pharmacia, Kalamazoo, MI). Marrow cells were prestimulated with 20 ng/mL murine interleukin-3 (IL-3), 50 ng/mL human IL-6, and 50 ng/mL rat stem cell factor (all generously provided by Amgen, Thousand Oaks, CA) in DMEM supplemented with 15% heat-inactivated FCS (Hyclone, Logan, UT). BM cells were subsequently cocultured with irradiated (1,200 cGy) viral producer cells using the above culture media supplemented with 6 µg/mL polybrene. Forty-eight hours later, nonadherent BM cells were gently rinsed off the producer cell monolayers, pelleted, and resuspended in fresh culture medium with the above cytokines. Cells were cultured for an additional 24 to 48 hours before analysis for expression of GFP or CD24 as described below, plated into methylcellulose media, or used for transplantation.
In vitro clonogenic progenitor assays.
Unsorted and sorted BM cells, in a volume not exceeding 150 µL, were suspended in 3 mL methylcellulose culture media (M3434; Stem Cell Technologies, Vancouver, British Columbia, Canada), which had been pretreated with 3 U thymidine phosphorylase at 37°C for 1 to 2 hours. Where specified, a stock solution of trimetrexate was added to the medium to obtain the desired drug concentration. After thorough mixing, cells were plated into 35-mm dishes. Cultures were incubated at 37°C in a 5% CO2 , humidified atmosphere and colonies enumerated after 7 to 10 days.
Transplantation of retroviral vector-transduced BM cells.
Transduced BM cells were washed twice and resuspended in phosphate-buffered saline (PBS) containing 2% FCS. Three to 5 × 106 cells were transplanted by tail-vein injection into lethally irradiated (900 cGy), congenic WB/B6 F1 +/+ recipient mice which differed in hemoglobin phenotype from the donor mice. Four weeks posttransplantation, PB obtained by retroorbital sinus puncture was analyzed for expression of GFP or CD24 as described below. Complete hematology parameters including hematocrit, platelet count, and total leukocyte counts were obtained by standard methods. Leukocyte differentials were obtained by scoring Wright-Giemsa-stained blood films. Hemoglobin analysis, to assess hematopoietic reconstitution by donor marrow, was performed by standard methods.39
Evaluation of GFP expression in cells and tissues.
In vitro cultured cells (fibroblasts and BM) were resuspended as single cells and directly subjected to flow cytometry with a FACS Vantage (Becton Dickinson, San Jose, CA) using excitation at 488 nm and fluorescence detection at 530 ± 30 nm (for GFP) or 575 ± 26 nm (for phycoerythrin). Propidium iodide (PI; Sigma, St Louis, MO) was added to all samples before analysis to allow identification and elimination of dead cells from the analysis. CD24 antibody staining of transduced marrow was performed using a murine IgG2a, phycoerythrin-conjugated, anti-CD24 monoclonal antibody (30785X; PharMingen, San Diego, CA) and was compared with staining using an isotype-matched control antibody. Before antibody staining of leukocytes, Fc receptors were blocked with a rat anti-CD16 antibody (Fc Block, 02141A; PharMingen). Plates containing hematopoietic colonies growing in methylcellulose were directly evaluated for GFP expression by visualization using a standard fluorescence microscope.
Expression of GFP in spleen colony-forming cells was evaluated by fluorescence microscopy using a wide-band green filter on fresh frozen, noncoverslipped 10-µm sections of spleens obtained from WB/B6 F1 +/+ animals that had been transplanted, after irradiation with 900 cGy, with 104 to 105 GFP- or CD24-transduced BM cells 13 days earlier. Photomicrographs were obtained using a Hamamatsu Low Light Level Camera (Hamamatsu Photonics K.K., Hamamatsu City, Japan) attached to a PC-based Leica Imaging System (Vashaw Scientific, Norcross, GA). Adjacent sections to those used for evaluation of GFP were stained with hematoxylin and eosin, dehydrated, coverslipped, and photographed using a Kontron digital camera attached to a Roche Image Analysis System (Roche Imaging Systems, Inc, Elon College, NC). Once all of the digital images were captured, they were imported and compiled into final figures using Adobe Photoshop software.
PB cells were analyzed for GFP expression as follows: whole blood was diluted 1:100 in PBS and used to assess GFP expression in red blood cells (RBCs) and platelets. Flow cytometry routinely revealed two easily distinguishable and characteristic populations, representing RBCs and platelets, based on forward and side light scatter parameters. These regions were used to gate on the respective populations for evaluation of GFP expression. As the contaminating leukocytes make up 1% or less of the total cell population, their presence did not significantly influence the analysis. To analyze GFP expression in the total leukocyte population, 300 to 500 µL of blood was depleted of RBCs by standard lysis procedures. After multiple washings with PBS/2% FCS, each followed by low-speed centrifugation, PI was added to the samples and the PI-dull, total leukocyte population was analyzed by flow cytometry.
| |
RESULTS |
Utilization of the GFP marker to generate high-titer, ecotropic GFP retroviral vector producer cells.
To investigate the potential utility of GFP as a selectable marker and reporter for gene transfer into hematopoietic cells, a murine stem cell virus (MSCV)-based retroviral vector, depicted in Fig 1B, was constructed as described in Materials and Methods. This bicistronic vector, MGirL22Y, contains the complete 714-bp GFP cDNA sequence linked by the encephalomyocarditis internal ribosome entry site to a human dihydrofolate reductase variant cDNA (termed L22Y), which confers high-level resistance to antifolate drugs such as trimetrexate. Conditioned media from transiently transfected 293T cells containing a high titer of amphotropic vector particles was used to multiply transduce the ecotropic packaging cell line GP+E86 and cells were subsequently selected for trimetrexate resistance. Flow cytometric analysis of the resulting trimetrexate-resistant polyclonal population, shown in Fig 2, showed intense fluorescence of all cells, demonstrating a concordance of expression of the two genes in the bicistronic vector. The brightest 10% of cells expressing GFP (Fig 2) was FACS sorted and expanded in culture. The viral titer of conditioned media obtained from this cell population, as assessed by transfer of trimetrexate resistance to NIH 3T3 cells, was approximately 5 × 106 colony-forming units (CFU)/mL. No toxic effects of GFP expression were observed despite extensive passaging of the cells in culture, and conditioned media from the producer cells exhibited a stable viral titer with passage of cells.
View larger version (16K):
[in this window]
[in a new window]
| Fig 2.
Flow cytometric analysis of GFP expression in GP + E86 cells transduced with amphotropic MGirL22Y vector particles after 7 days of selection with 100 nmol/L trimetrexate. The broken line profile designates the fluorescence of parental GP + E86 control cells while the solid line profile indicates the fluorescence of the GFP-transduced population. The proportion of cells sorted for high level GFP expression is indicated.
|
|
View larger version (136K):
[in this window]
[in a new window]
| Fig 3.
Phase contrast and fluorescence microscopy evaluation of GFP expression in murine hematopoietic colonies. (A) and (C) show colonies, derived from marrow transduced with the GFP vector, as visualized under phase contrast (original magnification × 80), while (B) and (D) demonstrate the same colonies under fluorescence microscopy performed on the identical fields shown in (A) and (C).
|
|
Southern blot analysis performed on MGirL22Y producer cell DNA showed the presence of an unrearranged proviral genomic band of expected size compared with the plasmid standard (Fig 1, lanes 3 and 1, respectively). Densitometry revealed the presence of an average of 15 proviral copies per cell in the MGirL22Y producer cells. Analysis of DNA from NIH 3T3 cells transduced with a low viral multiplicity of infection and subsequently selected with trimetrexate (to generate a cell line with approximately one proviral copy per cell) demonstrated faithful transmission of an intact, nonrearranged proviral genome (Fig 1, lane 5). Interestingly, on shorter exposures of the blot, a weakly intense, minor band was observed that was slightly smaller than the full-length provirus (data not shown). This probably represented a spliced, but transmitted, viral genome.
Assessment of retroviral gene transfer into murine myeloid and erythroid clonogenic progenitors using the GFP marker.
As shown in Fig 3, both myeloid and erythroid colonies derived from transduced progenitors expressed high levels of GFP as judged by direct visualization with phase contrast and fluorescence microscopy. Positive and negative colonies were easily discriminated from each other (Fig 3A and B) as there was no background autofluorescence observed in nontransduced cells. Colonies derived from BM cells transduced with a CD24 retroviral control vector also showed no detectable fluorescence (data not shown), indicating the specificity of GFP expression as a marker for retroviral gene transfer. Scoring of plates from three separate experiments showed a greater than 90% (618 of 656 hematopoietic colonies) overall transduction efficiency into clonogenic progenitors. A spectrum of intensity of GFP expression was readily observed ranging from dim, slightly positive colonies to colonies with very intense fluorescence.
Utilization of the GFP marker to enrich for clonogenic progenitors expressing increased levels of a linked, antifolate drug-resistance gene.
To evaluate the potential of using GFP as a selectable marker to enrich for hematopoietic cells expressing high levels of a second gene in a bicistronic transcript, murine BM cells were cocultivated with the GFP producer cells as above and subsequently analyzed for GFP expression by flow cytometry. As shown in a representative experiment, approximately 40% of the marrow cells (60% and 70%, respectively, in two other experiments) were very strongly positive for GFP expression (Fig 4A), while unstained, CD24-transduced BM cells showed no fluorescence. When stained with an anti-CD24 phycoerytherin-conjugated antibody, CD24-transduced cells consistently displayed fluorescence intensity at least two logs lower in magnitude than that measured for GFP-expressing cells (Fig 4B). Cells expressing high levels of GFP (Fig 4A) were FACS purified and plated in clonogenic progenitor cultures in the presence or absence of trimetrexate. As shown in a representative experiment, these cells displayed increased resistance to high concentrations of trimetrexate compared to the unsorted population (Fig 5), despite the fact that greater than 90% of unsorted progenitors were transduced as scored by GFP fluorescence in the absence of drug. Therefore, this strategy enables the efficient elimination of nontransduced and transduced, but low-level-expressing cells from cells expressing high levels of the bicistronic vector genome. As expected, all drug-resistant colonies showed GFP fluorescence, again confirming a high degree of concordance of expression of the two genes.
View larger version (24K):
[in this window]
[in a new window]
| Fig 4.
Flow cytometric analysis of GFP and CD24 expression in BM cells transduced with either the MGirL22Y vector or the CD24 vector. (A) Evaluation of GFP expression in BM cells 24 hours after completion of the transduction period. The broken line indicates the fluorescence profile of unstained, CD24-transduced control marrow while the solid line indicates the fluorescence profile of the GFP-transduced marrow. The extremely high level of fluorescence of the GFP-expressing cells necessitated the use of lower fluorescence amplification when analyzing for GFP expression. The proportion of positive cells in the population as well as the population expressing high levels of GFP that was FACS purified is shown. (B) Evaluation of CD24 expression in BM cells 24 hours after completion of the transduction period. The broken line indicates the fluorescence profile of GFP-transduced control marrow stained with an anti-CD24 antibody while the solid line indicates the fluorescence profile of the CD24-transduced marrow. The proportion of positive cells in the CD24-transduced population is shown.
|
|
View larger version (15K):
[in this window]
[in a new window]
| Fig 5.
Trimetrexate resistance of hematopoietic progenitors transduced with the MGirL22Y retroviral vector. Unsorted GFP-transduced marrow cells (dotted line), GFP-transduced marrow cells FACS sorted for high level expression of GFP (solid line), and mock-transduced marrow cells (broken line) were plated into methylcellulose cultures containing 0, 100, or 500 nmol/L trimetrexate as described in Materials and Methods. Five to eight days later, colonies were counted and percent survival, derived from the number of trimetrexate-resistant colonies divided by the number of colonies observed in the absence of drug, was determined.
|
|
Detection of retroviral gene transfer into day 13 spleen colony-forming cells (CFU-S) using the GFP marker.
BM cells transduced with the GFP vector or the CD24 vector as a control were injected into irradiated mice and 13 days later animals were sacrificed and spleens procured. Fresh frozen sections of spleens from GFP-transplanted and control-transplanted animals were then evaluated by fluorescence microscopy. Spleen colonies, identified morphologically by staining alternate sections with hematoxylin-eosin, derived from GFP-transduced progenitors displayed a range of fluorescence (Fig 6A and B), from very intense to dim. Higher magnification views (Fig 6C and D) showed the specificity of GFP marking in individual hematopoietic cells compared with the background splenic tissue. Not only were marked myeloid and erythroid cells discernible, but megakaryocytes were also intensely fluorescent (Fig 6C and D, arrow). No significant background fluorescence was detectable in spleens from control animals (Fig 6E and F). In an independent analysis, macroscopic, well-isolated spleen colonies from GFP-transplanted and control-transplanted animals were dissected and subsequently analyzed by flow cytometry. A significant proportion of cells (33% to 84%) in all 10 colonies evaluated which were derived from GFP-transduced progenitors displayed intense fluorescence, whereas control colonies contained no cells with a detectable fluorescent signal (data not shown).
View larger version (156K):
[in this window]
[in a new window]
| Fig 6.
Detection of gene transfer into day 12 spleen colony-forming cells using the GFP marker. Alternate, serial fresh frozen sections of spleens from animals transplanted with the GFP vector (A through D) or a control, CD24 vector (E and F) were stained with hematoxylin-eosin (A, C, and E) or directly visualized by fluorescence microscopy (B, D, and F) as described in Materials and Methods. In (A) and (B) the different arrows mark spleen hematopoietic colonies demonstrating a range of fluorescence intensities. In (C) and (D), the bold arrow denotes a GFP-marked megakaryocyte. Scale bars in (A) and (B) are equal to 325 µm, in (C) through (F) they are equal to 165 µm.
|
|
Transplantation of GFP-transduced BM cells into lethally irradiated mice leads to reconstitution of hematopoiesis with GFP-marked PB cell progeny.
To evaluate the potential of using GFP to track hematopoietic progeny in vivo after BM transplantation, a cohort of lethally irradiated mice was transplanted with congenic MGirL22Y-transduced or control CD24-transduced BM cells. In addition, several mice were transplanted with a 1:1 mixture of GFP- and control CD24-transduced marrow. Southern blot analysis performed on DNA from GFP-transduced BM showed high-level transfer of the unrearranged proviral genome (Fig 1, lane 7).
PB samples from reconstituted animals were analyzed by flow cytometry for GFP expression 4 weeks posttransplantation. RBCs, platelets, and leukocytes from animals reconstituted with GFP-transduced marrow displayed high-level fluorescence (Fig 7). Mice reconstituted with a 1:1 mixture of GFP- and CD24-transduced marrow also had brightly fluorescent cells in all lineages. In contrast, blood elements from mice reconstituted with CD24-transduced marrow had no significant level of background fluorescence.
View larger version (20K):
[in this window]
[in a new window]
| Fig 7.
Reconstitution of hematopoiesis with GFP-marked PB cells in lethally irradiated animals transplanted with GFP-transduced BM. Flow cytometric analysis of GFP expression in RBCs, platelets, and leukocytes was performed as described in Materials and Methods. For the white blood cell (WBC) panel, very high-level GFP fluorescence in expressing cells necessitated analysis using lower fluorescence amplification for all the WBC samples. The profiles of representative animals transplanted with marrow transduced with the control CD24 vector, the MGirL22Y vector, or an equal number of MGirL22Y- and CD24-transduced marrow cells 4 weeks posttransplantation are shown as indicated. The proportion of GFP-positive cells within each respective population is indicated.
|
|
Most of the mice reconstituted with GFP-transduced marrow (n = 8) typically displayed a 70% to 90% range of GFP-marking of cells within each lineage, consistent with the degree of engraftment of donor cells as assessed in the erythroid lineage by hemoglobin electrophoresis (data not shown). Mice reconstituted with a 1:1 mixture of GFP- and control-transduced marrow (n = 4) displayed a range of 30% to 50% marking in leukocytes and platelets and 20% to 25% in RBCs. PB films from these animals showed concordance of the flow cytometry data with the degree of cell positivity estimated by direct visualization using fluorescence microscopy (Fig 8, see page 1780). Intense fluorescence was easily observed in individual leukocytes and platelets, while RBCs appeared dimmer. In contrast, evaluation of blood films obtained from animals transplanted with marrow transduced with the control, CD24 vector demonstrated the absence of detectable cell fluorescence (data not shown). No abnormalities in hematopoiesis have been observed in mice reconstituted with GFP-transduced marrow as judged by engraftment, complete blood counts, and blood cell morphology (data not shown).
View larger version (142K):
[in this window]
[in a new window]
| Fig 8.
Direct microscopic visualization of genetically modified PB cell progeny using the GFP marker. Photomicrographs (original magnification × 2,000) of the identical field from a PB film obtained from an animal transplanted with GFP-transduced marrow both before (B), and after, staining with Wright-Giemsa (A) are shown. The arrowhead denotes a granulocyte exhibiting bright fluorescence while the arrows mark a very weakly fluorescent granulocyte (top arrow) and a mononuclear cell lacking fluorescence (bottom arrow).
|
|
| |
DISCUSSION |
Our work has shown that the GFP gene can serve as a very useful marker of genetic modification of hematopoietic cells. Selection of primitive hematopoietic cells ex vivo, based on the presence and level of GFP expression, provides a population of transduced cells with the high level of expression of a linked, drug-resistance marker gene encoded with GFP in a bicistronic transcript. By virtue of its intrinsic fluorescence, GFP is readily detected in tissues and PB cells, providing a convenient strategy to track the behavior of genetically modified cells.
Although the human CD24 molecule and its murine homologue, the heat-stable antigen,40 have been shown by others to be useful as selectable markers for identifying and enriching transduced hematopoietic cells,22,23 each has associated limitations. The use of the CD24 marker in human cells is restricted because of its endogenous expression on hematopoietic and immune tissues.41 Both CD24 and heat-stable antigen, which has been proposed as an alternate marker for use in human cells,23 suffer shortcomings because of their putative roles as immune regulatory molecules.41-44 Interestingly, human CD24 has also recently been reported to be a major ligand for P-selectin,45 which is involved in platelet adherence to leukocytes and endothelial cells. Unlike GFP, these markers cannot be used to directly determine gene transfer into in vitro clonogenic progenitors grown in methylcellulose because of the requirement for antibody staining. Other advantages of using the GFP marker are the elimination of potential undesired effects of antibody staining (crosslinking of cell-surface membrane proteins), as well as its associated costs. Furthermore, the lack of necessity for extensive cell manipulation, as occurs during antibody staining protocols, when preparing GFP-transduced cells for FACS purification is not only a theoretical benefit, but a practical one when large numbers of purified cells are desired.
Another issue with regard to the use of proteins such as CD24, which are attached to the cell membrane via a glycophosphoinositol (GPI) anchor, is their propensity to be transferred from expressing to nonexpressing cells.46,47 Indeed, we have observed that the proportion of leukocytes that display the CD24 marker consistently exceeds the proportion of marked RBCs and platelets in animals transplanted with CD24-transduced BM cells (J. Allay and B. Sorrentino, unpublished observations, November 1996). Preliminary analysis has led to the detection of leukocytes expressing both the CD24 and GFP markers in our animals which were transplanted with the mixture of CD24- and MGirL22Y-transduced cells (unpublished observations, May 1997). Our prediction is that such double-marked cells will contain the MGirL22Y genome but lack the genome for the CD24 virus.
As suggested by others,21-23 the use of retroviral vectors containing markers not normally present on target cells to facilitate enrichment of transduced cells can enable BM transplantation or adoptive immunotherapy to be performed with pure populations of genetically modified cells. For this to be practical on even a modest preclinical scale, transduced cells must be easily discriminated from nontransduced cells, and if desired, low-level-expressing, transduced cells. In this regard, the GFP marker, which demonstrates markedly intense fluorescence in transduced marrow cells in our studies, appears to be an outstanding selectable marker. In contrast, we have found that the CD24 marker (Fig 4), as have others with both the CD24 and HSA markers,22,23 as detected by immunofluorescence techniques, display at least two logs lower fluorescence intensity than that of GFP in transduced marrow cells. Although this could be due in part to vector design and viral producer cell titer, it would be highly unusual for an antibody staining technique to yield fluorescence intensity comparable to that observed with GFP in these studies. In this regard, the fluorescence intensity of the GFP marker in transduced BM cells facilitates discrimination of genetically modified cells from unmodified cells. For FACS purification strategies, this enables sort gates to be less stringently designated, even for high-level-expressing, positive cells, leading to an increased yield of highly purified cells. Preliminary experiments have shown the ability to obtain large numbers of purified, transduced BM cells expressing high levels of GFP. The GFP marker could potentially prove to be a powerful tool to highly enrich large numbers of cells expressing a linked therapeutic gene.
In addition to its utilities as a selectable marker and in detecting the progeny of genetically modified hematopoietic cells of all lineages in the spleen and PB, the GFP marker gene holds significant potential in facilitating the in vivo tracking of migration of lymphoid and monocytic cells derived from transplanted marrow. In this regard, gene-modified B and T lymphocytes display high-level GFP expression in mice 6 weeks posttransplantation with GFP-transduced marrow cells (J. Riberdy, J. Allay, D. Persons, and P. Doherty, unpublished observations, May 1997). Experiments designed to follow the movements of various phentoypically defined lymphocyte subpopulations in immune tissues in response to a wide array of antigenic challenges are underway. Likewise, tracking of gene-corrected phagocytic cells into the central nervous system in the setting of murine models of lipid storage diseases48 may yield information pertinent to the design of improved gene therapy strategies for these diseases.
Recent reports have emphasized the importance of a potential host immune response to the transgene product in genetically modified cells.4,49-52 Such immune responses have not generally been documented in irradiated mice that are recipients of genetically modified cells. Therefore, the relative immunogenicity of GFP compared with other markers such as murine heat-stable antigen or the low-affinity nerve growth factor receptor remains to be determined. Experiments designed to directly assess the immunogenecity of GFP in nonhuman primates transplanted with MGirL22Y-transduced BM may be informative.
Our studies show that GFP can serve as an excellent marker of gene transfer in hematopoietic tissues. Its utilization in human gene-marking trials will allow purification of genetically modified cells ex vivo and the tracking of such cells following transplantation. Evaluation of various methodologies for gene transfer into immunophenotypically defined, rare cell populations, such as the hematopoietic stem cell, should be facilitated by the use of the GFP marker.
| |
FOOTNOTES |
Submitted June 3, 1997;
accepted June 16, 1997.
Supported in part by National Heart, Lung and Blood Institute Program Project P01 HL 53749-01, Cancer Center Support CORE Grant P30 CA 21765, National Institutes of Health Grant No. CA 70089, and American Lebanese Syrian Associated Charities (ALSAC).
Address reprint requests to Arthur W. Nienhuis, MD, Director, St Jude Children's Research Hospital, 332 N Lauderdale Dr, Memphis, TN 38105-2794.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors thank Elio Vanin and John Cunningham for helpful advice and stimulating discussions. We thank John Zachar for his help in fluorescence microscopy and Jean Johnson for help in preparing this manuscript.
| |
REFERENCES |
1. Nienhuis AW, Walsh CE, Liu J: Viruses as therapeutic gene transfer vectors, in Young NS (ed): Viruses and Bone Marrow. New York, NY, Dekker, 1993, p 353
2.
Miller AD,
Miller DG,
Garcia JV,
Lynch CM:
Use of retroviral vectors for gene transfer and expression.
Methods Enzymol
217:581,
1993[Medline]
[Order article via Infotrieve]
3.
Leboulch P,
Huang GM,
Humphries RK,
Oh YH,
Eaves CJ,
Tuan DY,
London IM:
Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure.
EMBO J
13:3065,
1994[Medline]
[Order article via Infotrieve]
4.
Kohn DB,
Weinberg KI,
Nolta JA,
Heiss LN,
Lenarsky C,
Crooks GM,
Hanley ME,
Annett G,
Brooks JS,
el-Khoureiy A,
Lawrence K,
Wells S,
Moen RC,
Bastian J,
Williams-Herman DE,
Elder M,
Wara D,
Bowen T,
Hershfield MS,
Mullen CA,
Blaese RM,
Parkman R:
Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
Nat Med
1:1017,
1995[Medline]
[Order article via Infotrieve]
5.
Blaese RM,
Culver KW,
Miller AD,
Carter CS,
Fleisher T,
Clerici M,
Shearer G,
Chang L,
Chiang Y,
Tolstoshev P,
Greenblatt JJ,
Rosenberg SA,
Klein H,
Berger M,
Mullen CA,
Ramsey WJ,
Muul L,
Morgan RA,
Anderson WF:
T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years.
Science
270:475,
1995[Abstract/Free Full Text]
6.
Poeschla E,
Corbeau P,
Wong-Staal F:
Development of HIV vectors for anti-HIV gene therapy.
Proc Natl Acad Sci USA
93:11395,
1996[Abstract/Free Full Text]
7.
Roth JA,
Cristiano RJ:
Gene therapy for cancer: What have we done and where are we going?
J Natl Cancer Inst
89:21,
1997[Abstract/Free Full Text]
8.
Sorrentino BP,
Brandt SJ,
Bodine D,
Gottesman M,
Pastan L,
Cline A,
Nienhuis AW:
Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1.
Science
257:99,
1992[Abstract/Free Full Text]
9.
Bodine DM,
Karlsson S,
Nienhuis AW:
Combination of interleukin 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.
Proc Natl Acad Sci USA
86:9987,
1989
10.
Dunbar CE,
Cottler-Fox M,
O'Shaughnessy JA,
Doren S,
Carter CS,
Berenson R,
Brown S,
Moen RC,
Greenblat J,
Stewart FM,
Leitman SF,
Wilson W,
Cowan KH,
Young NS,
Nienhuis AW:
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Blood
85:3048,
1995[Abstract/Free Full Text]
11.
Dunbar CE:
Gene transfer into hematopoietic stem cells: Implications for gene therapy of human disease.
Annu Rev Med
47:11,
1996[Medline]
[Order article via Infotrieve]
12.
Brenner MK:
Gene transfer into hematopoietic cells.
N Engl J Med
335:337,
1996[Free Full Text]
13.
Keller G,
Paige C,
Gilboa E,
Wagner EF:
Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent hematopoietic precursors.
Nature
318:149,
1985[Medline]
[Order article via Infotrieve]
14.
Paulus W,
Baur I,
Boyce FM,
Breakefield XO,
Reeves SA:
Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells.
J Virol
70:62,
1996[Abstract]
15.
Yang Z,
Korman AJ,
Cooper J,
Pious D,
Accolla RS,
Mulligan RC,
Strominger JL:
Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.
Mol Cell Biol
7:3923,
1987[Abstract/Free Full Text]
16.
Strair RK,
Towle M,
Smith BR:
Retroviral mediated gene transfer into bone marrow progenitor cells: Use of beta-galactosidase as a selectable marker.
Nucleic Acids Res
18:4759,
1990[Abstract/Free Full Text]
17.
Fields-Berry SC,
Holliday AL,
Cepko CL:
A recombinant retrovirus encoding alkaline phosphatase confirms clonal boundary assignment in lineage analysis of murine retina.
Proc Natl Acad Sci USA
89:693,
1992[Abstract/Free Full Text]
18.
Lynch CM,
Clowes MM,
Osborne WRA,
Clowes AW,
Miller AD:
Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy.
Proc Natl Acad Sci USA
89:1138,
1992[Abstract/Free Full Text]
19.
Nolan GP,
Fiering S,
Nicolas J-F,
Herzenberg LA:
Fluorescence-activated cell analysis and sorting of viable mammalian cells based on -D-galactosidase activity after transduction of Escherichia coli lacZ.
Proc Natl Acad Sci USA
85:2603,
1988[Abstract/Free Full Text]
20.
Ward M,
Richardson C,
Pioli P,
Smith L,
Podda S,
Goff S,
Hesdorffer C,
Bank A:
Transfer and expression of the human multiple drug resistance gene in human CD34+ cells.
Blood
84:1408,
1994[Abstract/Free Full Text]
21.
Mavilio F,
Ferrari G,
Rossini S,
Nobili N,
Bonini C,
Casorati G,
Traversari C,
Bordignon C:
Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer.
Blood
83:1988,
1994[Abstract/Free Full Text]
22.
Pawliuk R,
Kay R,
Lansdorp P,
Humphries RK:
Selection of retrovirally transduced hematopoietic cells using CD24 as a marker of gene transfer.
Blood
84:2868,
1994[Abstract/Free Full Text]
23.
Conneally E,
Bardy P,
Eaves CJ,
Thomas T,
Chappel S,
Shpall EJ,
Humphries RK:
Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer.
Blood
87:456,
1996[Abstract/Free Full Text]
24.
Chalfie M,
Tu Y,
Euskirchen G,
Ward WW,
Prasher DC:
Green fluorescent protein as a marker for gene expression.
Science
263:802,
1994[Abstract/Free Full Text]
25.
Cody CW,
Prasher DC,
Westler WM,
Prendergast FG,
Ward WW:
Chemical structure of the hexapeptide chromophore of the Aequorea green fluorescent protein.
Biochemistry
32:1212,
1993[Medline]
[Order article via Infotrieve]
26.
Zolotukhin S,
Potter M,
Hauswirth WW,
Guy J,
Muzyczka N:
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.
J Virol
70:4646,
1996[Abstract]
27.
Yang TT,
Cheng L,
Kain SR:
Optimized codon usage and chromophore mutations provide enhanced sensitivity with the green fluorescent protein.
Nucleic Acids Res
24:4592,
1996[Abstract/Free Full Text]
28.
Kain SR,
Adams M,
Kondepudi A,
Yang TT,
Ward WW,
Kitts P:
Green fluorescent protein as a reporter of gene expression and protein localization.
Biotechniques
19:650,
1995[Medline]
[Order article via Infotrieve]
29.
Ikawa M,
Kominami K,
Yoshimura Y,
Tanaka K,
Nishimune Y,
Okabe M:
Green fluorescent protein as a marker in transgenic mice.
Develop Growth Differ
37:455,
1995
30.
Cheng L,
Fu J,
Tsukamoto A,
Hawley RG:
Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells.
Nature Biotechology
14:606,
1996[Medline]
[Order article via Infotrieve]
31.
Levy JP,
Muldoon RR,
Zolotukhin S,
Link CJ Jr:
Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells.
Nat Biotech
14:610,
1996[Medline]
[Order article via Infotrieve]
32.
Markowitz D,
Goff S,
Bank A:
A safe packaging line for gene transfer: Separating viral genes on two different plasmids.
J Virol
62:1120,
1988[Abstract/Free Full Text]
33.
Dubridge RB,
Tang P,
Hsia HC,
Phaik-Mooi L,
Miller JH,
Calos MP:
Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.
Mol Cell Biol
7:379,
1987[Abstract/Free Full Text]
34.
Hawley RG,
Lieu FHL,
Fong AZC,
Hawley TS:
Versatile retroviral vectors for potential use in gene therapy.
Gene Ther
1:136,
1994[Medline]
[Order article via Infotrieve]
35.
Migita M,
Medin JA,
Pawliuk R,
Jacobson S,
Nagle JW,
Anderson S,
Amiri M,
Humphries RK,
Karlsson S:
Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors.
Proc Natl Acad Sci USA
92:12075,
1995[Abstract/Free Full Text]
36.
Spencer HT,
Sleep SEH,
Rehg JE,
Blakley RL,
Sorrentino BP:
A gene transfer strategy for making bone marrow cells resistant to trimetrexate.
Blood
87:2579,
1996[Abstract/Free Full Text]
37. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning, A Laboratory Manual (ed 2). Plainview, NY, Cold Spring Harbor Laboratory, 1989
38.
Allay J,
Dumenco L,
Omer N,
Liu L,
Gerson S:
Retroviral transduction and expression of the human alkyltransfersase cDNA provides nitrosourea resistance to hematopoietic cells.
Blood
85:3342,
1995[Abstract/Free Full Text]
39.
Whitney JB:
Simplified typing of mouse hemoglobins (Hbb) phenotypes using cystamine.
Biochem Genet
16:667,
1978[Medline]
[Order article via Infotrieve]
40.
Kay R,
Takei F,
Humphries RK:
Expression cloning of a NA encoding M1/69-J11d heat stable antigen.
J Immunol
5:1952,
1990
41.
Fischer G-F,
Majdic O,
Gadd S,
Knapp W:
Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules.
J Immunol
144:638,
1990[Abstract]
42.
Kay R,
Rosten PM,
Humphries RK:
Signal transducer modulating B cell activation responses, is a very short peptide with a glycosylphosphatidylinositol membrane anchor.
J Immunol
147:1412,
1991[Abstract]
43.
Hough MR,
Takei F,
Humphries RK,
Kay R:
Defective development of thymocytes overexpressing the costimulatory molecule, heat-stable antigen.
J Exp Med
179:177,
1994[Abstract/Free Full Text]
44.
Liu Y,
Jones B,
Aruffo A,
Sullivan KM,
Linsley PS,
Janeway CA:
Heat-stable antigen is a costimulatory molecule for CD4 T cell growth.
J Exp Med
175:437,
1992[Abstract/Free Full Text]
45.
Aigner S,
Sthoeger M,
Fogel M,
Weber E,
Zarn J,
Ruppert M,
Yvonka Z,
Vestweber D,
Stahel R,
Sammar M,
Altevogt P:
CD24, a mucin-type glycoprotein, is a ligand for p-selectin on human tumor cells.
Blood
89:3385,
1997[Abstract/Free Full Text]
46.
Dunn DE,
Yu J,
Nagarajan S,
Devetten M,
Weichold FF,
Medof ME,
Young NS,
Liu JM:
A knock-out model of paroxysmal nocturnal hemoglobinuria: Pig-a hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins.
Proc Natl Acad Sci USA
93:7938,
1996[Abstract/Free Full Text]
47.
Kooyman DL,
Byrne GW,
McClellan S,
Nielsen D,
Tone M,
Waldmann H,
Coffman TM,
McCurry KR,
Platt JL,
Logan JS:
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium.
Science
269:89,
1995[Abstract/Free Full Text]
48.
Zhou XY,
Morreau H,
Rottier R,
Davis D,
Bonten E,
Gillemans N,
Wenger D,
Grosveld FG,
Doherty P,
Suzuki K,
Grosveld GC,
d'Azzo A:
Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with over-expressing erythroid precursor cells.
Genes Dev
9:2623,
1995[Abstract/Free Full Text]
49.
Brenner MK:
Gene marking.
Hum Gene Ther
7:1927,
1996[Medline]
[Order article via Infotrieve]
50.
Dao MA,
Hannum CH,
Kohn DB,
Nolta JA:
FLT3 ligand preserves the ability to human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction.
Blood
89:446,
1997[Abstract/Free Full Text]
51.
Tripathy SK,
Black HB,
Goldwasser E,
Leiden JM:
Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.
Nat Med
2:545,
1996[Medline]
[Order article via Infotrieve]
52.
Riddell SR,
Elliot M,
Lewinsohn DA,
Gilbert MJ,
Wilson L,
Manley SA,
Lupton SD,
Overell RW,
Reynolds TC,
Corey L,
Greenberg PD:
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients.
Nat Med
2:216,
1996[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Rubtsova, J. P. Scott-Browne, F. Crawford, S. Dai, P. Marrack, and J. W. Kappler
Many different V{beta} CDR3s can reveal the inherent MHC reactivity of germline-encoded TCR V regions
PNAS,
May 12, 2009;
106(19):
7951 - 7956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mumprecht, C. Claus, C. Schurch, V. Pavelic, M. S. Matter, and A. F. Ochsenbein
Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells
Blood,
May 7, 2009;
113(19):
4681 - 4689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Alli, P. Nguyen, and T. L. Geiger
Retrogenic Modeling of Experimental Allergic Encephalomyelitis Associates T Cell Frequency but Not TCR Functional Affinity with Pathogenicity
J. Immunol.,
July 1, 2008;
181(1):
136 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dominici, R. Marino, V. Rasini, C. Spano, P. Paolucci, P. Conte, T. J. Hofmann, and E. M. Horwitz
Donor cell-derived osteopoiesis originates from a self-renewing stem cell with a limited regenerative contribution after transplantation
Blood,
April 15, 2008;
111(8):
4386 - 4391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Z. Lieu, J. G. Lock, L. A. Hammond, N. L. La Gruta, J. L. Stow, and P. A. Gleeson
A trans-Golgi network golgin is required for the regulated secretion of TNF in activated macrophages in vivo
PNAS,
March 4, 2008;
105(9):
3351 - 3356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Moisini, P. Nguyen, L. Fugger, and T. L. Geiger
Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-{zeta} Chimeric Receptor
J. Immunol.,
March 1, 2008;
180(5):
3601 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Gori, K. Podetz-Pedersen, D. Swanson, A. D. Karlen, R. Gunther, N. V. Somia, and R. S. McIvor
Protection of Mice from Methotrexate Toxicity by ex Vivo Transduction Using Lentivirus Vectors Expressing Drug-Resistant Dihydrofolate Reductase
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
989 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Dobbs, T. Yang, D. Farmer, L. Kager, O. Parolini, and M. E. Conley
Cutting Edge: A Hypomorphic Mutation in Igbeta (CD79b) in a Patient with Immunodeficiency and a Leaky Defect in B Cell Development
J. Immunol.,
August 15, 2007;
179(4):
2055 - 2059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Schuster, L. Fan, and L. C. Harris
MDM2 Splice Variants Predominantly Localize to the Nucleoplasm Mediated by a COOH-Terminal Nuclear Localization Signal
Mol. Cancer Res.,
April 1, 2007;
5(4):
403 - 412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. El Kasmi, J. Holst, M. Coffre, L. Mielke, A. de Pauw, N. Lhocine, A. M. Smith, R. Rutschman, D. Kaushal, Y. Shen, et al.
General Nature of the STAT3-Activated Anti-Inflammatory Response
J. Immunol.,
December 1, 2006;
177(11):
7880 - 7888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Priller, M. Prinz, M. Heikenwalder, N. Zeller, P. Schwarz, F. L. Heppner, and A. Aguzzi
Early and Rapid Engraftment of Bone Marrow-Derived Microglia in Scrapie.
J. Neurosci.,
November 8, 2006;
26(45):
11753 - 11762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Seggewiss, S. Pittaluga, R. L. Adler, F. J. Guenaga, C. Ferguson, I. H. Pilz, B. Ryu, B. P. Sorrentino, W. S. Young III, R. E. Donahue, et al.
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque
Blood,
May 15, 2006;
107(10):
3865 - 3867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carella, M. Potter, J. Bonten, J. E. Rehg, G. Neale, and G. C. Grosveld
The ETS factor TEL2 is a hematopoietic oncoprotein
Blood,
February 1, 2006;
107(3):
1124 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Szymczak, C. J. Workman, D. Gil, S. Dilioglou, K. M. Vignali, E. Palmer, and D. A. A. Vignali
The CD3{epsilon} Proline-Rich Sequence, and Its Interaction with Nck, Is Not Required for T Cell Development and Function
J. Immunol.,
July 1, 2005;
175(1):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cardone, A. Kandilci, C. Carella, J. A. Nilsson, J. A. Brennan, S. Sirma, U. Ozbek, K. Boyd, J. L. Cleveland, and G. C. Grosveld
The Novel ETS Factor TEL2 Cooperates with Myc in B Lymphomagenesis
Mol. Cell. Biol.,
March 15, 2005;
25(6):
2395 - 2405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Workman and D. A. A. Vignali
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)
J. Immunol.,
January 15, 2005;
174(2):
688 - 695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kawahara, Y. Ogo, H. Ueda, and T. Nagamune
Improved growth response of antibody/receptor chimera attained by the engineering of transmembrane domain
Protein Eng. Des. Sel.,
October 1, 2004;
17(10):
715 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kawagoe, M. Potter, J. Ellis, and G. C. Grosveld
TEL2, an ETS Factor Expressed in Human Leukemia, Regulates Monocytic Differentiation of U937 Cells and Blocks the Inhibitory Effect of TEL1 on Ras-Induced Cellular Transformation
Cancer Res.,
September 1, 2004;
64(17):
6091 - 6100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Y. Arnold, A. R. Burton, and D. A. A. Vignali
Diabetes Incidence Is Unaltered in Glutamate Decarboxylase 65-Specific TCR Retrogenic Nonobese Diabetic Mice: Generation by Retroviral-Mediated Stem Cell Gene Transfer
J. Immunol.,
September 1, 2004;
173(5):
3103 - 3111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sasaki, C. T. Jensen, S. Karlsson, and S. E. W. Jacobsen
Enforced expression of cyclin D2 enhances the proliferative potential of myeloid progenitors, accelerates in vivo myeloid reconstitution, and promotes rescue of mice from lethal myeloablation
Blood,
August 15, 2004;
104(4):
986 - 992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dominici, C. Pritchard, J. E. Garlits, T. J. Hofmann, D. A. Persons, and E. M. Horwitz
Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation
PNAS,
August 10, 2004;
101(32):
11761 - 11766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, I. R. Williams, J. L. Kutok, N. Duclos, E. Anastasiadou, S. C. Masters, H. Fu, and D. G. Gilliland
Positive and negative regulatory roles of the WW-like domain in TEL-PDGF{beta}R transformation
Blood,
July 15, 2004;
104(2):
535 - 542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Persons, J. A. Allay, A. Bonifacino, T. Lu, B. Agricola, M. E. Metzger, R. E. Donahue, C. E. Dunbar, and B. P. Sorrentino
Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors
Blood,
February 1, 2004;
103(3):
796 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Nguyen, I. Moisini, and T. L. Geiger
Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function
Blood,
December 15, 2003;
102(13):
4320 - 4325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Kreklau, K. E. Pollok, B. J. Bailey, N. Liu, J. R. Hartwell, D. A. Williams, and L. C. Erickson
Hematopoietic expression of O6-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea
Mol. Cancer Ther.,
December 1, 2003;
2(12):
1321 - 1329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xu, S. Huang, L.-S. Chang, A. D. Agulnick, and S. J. Brandt
Identification of a TAL1 Target Gene Reveals a Positive Role for the LIM Domain-Binding Protein Ldb1 in Erythroid Gene Expression and Differentiation
Mol. Cell. Biol.,
November 1, 2003;
23(21):
7585 - 7599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Strom, S. J. Turner, S. Andreansky, H. Liu, P. C. Doherty, D. K. Srivastava, J. M. Cunningham, and A. W. Nienhuis
Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells
Blood,
November 1, 2003;
102(9):
3108 - 3116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kurre, J. Morris, B. Thomasson, D. B. Kohn, and H.-P. Kiem
Scaffold attachment region-containing retrovirus vectors improve long-term proviral expression after transplantation of GFP-modified CD34+ baboon repopulating cells
Blood,
November 1, 2003;
102(9):
3117 - 3119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tajima, T. Tanaka, T. Ebata, K. Takeda, A. Kawasaki, J. M. Kelly, P. K. Darcy, R. E. Vance, D. H. Raulet, K. Kinoshita, et al.
Blastocyst MHC, a Putative Murine Homologue of HLA-G, Protects TAP-Deficient Tumor Cells from Natural Killer Cell-Mediated Rejection In Vivo
J. Immunol.,
August 15, 2003;
171(4):
1715 - 1721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kawahara, H. Ueda, S. Morita, K. Tsumoto, I. Kumagai, and T. Nagamune
Bypassing antibiotic selection: positive screening of genetically modified cells with an antigen-dependent proliferation switch
Nucleic Acids Res.,
April 1, 2003;
31(7):
e32 - e32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Persons, P. W. Hargrove, E. R. Allay, H. Hanawa, and A. W. Nienhuis
The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma -globin gene is influenced by chromosomal position effects and vector copy number
Blood,
March 15, 2003;
101(6):
2175 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-L. Kuo, E. J. Duncavage, R. Mathew, W. den Besten, D. Pei, D. Naeve, T. Yamamoto, C. Cheng, C. J. Sherr, and M. F. Roussel
Arf Induces p53-dependent and -independent Antiproliferative Genes
Cancer Res.,
March 1, 2003;
63(5):
1046 - 1053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Desmond, J. C. Mountford, M. T. Drayson, E. A. Walker, M. Hewison, J. P. Ride, Q. T. Luong, R. E. Hayden, E. F. Vanin, and C. M. Bunce
The Aldo-Keto Reductase AKR1C3 Is a Novel Suppressor of Cell Differentiation That Provides a Plausible Target for the Non-Cyclooxygenase-dependent Antineoplastic Actions of Nonsteroidal Anti-Inflammatory Drugs
Cancer Res.,
January 15, 2003;
63(2):
505 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Grove, C. Lutzko, J. Priller, O. Henegariu, N. D. Theise, D. B. Kohn, and D. S. Krause
Marrow-Derived Cells as Vehicles for Delivery of Gene Therapy to Pulmonary Epithelium
Am. J. Respir. Cell Mol. Biol.,
December 1, 2002;
27(6):
645 - 651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Workman, K. J. Dugger, and D. A. A. Vignali
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3
J. Immunol.,
November 15, 2002;
169(10):
5392 - 5395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Knoetig, T. A. Torrey, Z. Naghashfar, T. McCarty, and H. C. Morse III
CD19 Signaling Pathways Play a Major Role for Murine AIDS Induction and Progression
J. Immunol.,
November 15, 2002;
169(10):
5607 - 5614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Otsu, M. Steinberg, C. Ferrand, P. Merida, C. Rebouissou, P. Tiberghien, N. Taylor, F. Candotti, and N. Noraz
Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells
Blood,
July 30, 2002;
100(4):
1248 - 1256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Kelly, J. L. Kutok, I. R. Williams, C. L. Boulton, S. M. Amaral, D. P. Curley, T. J. Ley, and D. G. Gilliland
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
PNAS,
June 11, 2002;
99(12):
8283 - 8288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Leimig, L. Mann, M. d. P. Martin, E. Bonten, D. Persons, J. Knowles, J. A. Allay, J. Cunningham, A. W. Nienhuis, R. Smeyne, et al.
Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells
Blood,
May 1, 2002;
99(9):
3169 - 3178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dang, M.-L. Kuo, C. M. Eischen, L. Stepanova, C. J. Sherr, and M. F. Roussel
The RING Domain of Mdm2 Can Inhibit Cell Proliferation
Cancer Res.,
February 1, 2002;
62(4):
1222 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
Blood,
January 1, 2002;
99(1):
310 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Dervieux, J. G. Blanco, E. Y. Krynetski, E. F. Vanin, M. F. Roussel, and M. V. Relling
Differing Contribution of Thiopurine Methyltransferase to Mercaptopurine versus Thioguanine Effects in Human Leukemic Cells
Cancer Res.,
August 1, 2001;
61(15):
5810 - 5816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Vassilopoulos, G. Trobridge, N. C. Josephson, and D. W. Russell
Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors
Blood,
August 1, 2001;
98(3):
604 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Frantsve, J. Schwaller, D. W. Sternberg, J. Kutok, and D. G. Gilliland
Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation
Mol. Cell. Biol.,
May 15, 2001;
21(10):
3547 - 3557.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. C. Nathwani, A. Davidoff, H. Hanawa, J.-F. Zhou, E. F. Vanin, and A. W. Nienhuis
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA
Blood,
March 1, 2001;
97(5):
1258 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Hamaguchi, N.-B. Woods, I. Panagopoulos, E. Andersson, H. Mikkola, C. Fahlman, R. Zufferey, L. Carlsson, D. Trono, and S. Karlsson
Lentivirus Vector Gene Expression during ES Cell-Derived Hematopoietic Development In Vitro
J. Virol.,
November 15, 2000;
74(22):
10778 - 10784.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Ragg, M. Xu-Welliver, J. Bailey, M. D’Souza, R. Cooper, S. Chandra, R. Seshadri, A. E. Pegg, and D. A. Williams
Direct Reversal of DNA Damage by Mutant Methyltransferase Protein Protects Mice against Dose-intensified Chemotherapy and Leads to in Vivo Selection of Hematopoietic Stem Cells
Cancer Res.,
September 1, 2000;
60(18):
5187 - 5195.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. G. Stevenson, S. Efstathiou, P. C. Doherty, and P. J. Lehner
Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses
PNAS,
July 5, 2000;
(2000)
150240097.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. C. Quackenbush, G. W. Reuther, J. P. Miller, K. D. Courtney, W. S. Pear, and A. M. Pendergast
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
Blood,
May 1, 2000;
95(9):
2913 - 2921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Patel, J. A. Allay, J. A. Belt, and B. P. Sorrentino
Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells
Blood,
April 1, 2000;
95(7):
2356 - 2363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Huang and S. J. Brandt
mSin3A Regulates Murine Erythroleukemia Cell Differentiation through Association with the TAL1 (or SCL) Transcription Factor
Mol. Cell. Biol.,
March 15, 2000;
20(6):
2248 - 2259.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Kieslinger, I. Woldman, R. Moriggl, J. Hofmann, J.-C. Marine, J. N. Ihle, H. Beug, and T. Decker
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation
Genes & Dev.,
January 15, 2000;
14(2):
232 - 244.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. E. Donahue, R. P. Wersto, J. A. Allay, B. A. Agricola, M. E. Metzger, A. W. Nienhuis, D. A. Persons, and B. P. Sorrentino
High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34+ cells
Blood,
January 15, 2000;
95(2):
445 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Williams, A. W. Nienhuis, R. G. Hawley, and F. O. Smith
Gene Therapy 2000
Hematology,
January 1, 2000;
2000(1):
376 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Halene, L. Wang, R. M. Cooper, D. C. Bockstoce, P. B. Robbins, and D. B. Kohn
Improved Expression in Hematopoietic and Lymphoid Cells in Mice After Transplantation of Bone Marrow Transduced With a Modified Retroviral Vector
Blood,
November 15, 1999;
94(10):
3349 - 3357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kume, M. Hashiyama, T. Suda, and K. Ozawa
Green Fluorescent Protein as a Selectable Marker of Retrovirally Transduced Hematopoietic Progenitors
Stem Cells,
July 1, 1999;
17(4):
226 - 232.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. L. Holmes, J. D. Haley, L. Cerruti, W.-l. Zhou, H. Zogos, D. E. Smith, J. M. Cunningham, and S. M. Jane
Identification of Id2 as a Globin Regulatory Protein by Representational Difference Analysis of K562 Cells Induced To Express gamma -Globin with a Fungal Compound
Mol. Cell. Biol.,
June 1, 1999;
19(6):
4182 - 4190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E.J. Pritchard, M. Fornerod, L. H. Kasper, and J. M.A. van Deursen
RAE1 Is a Shuttling mRNA Export Factor That Binds to a GLEBS-like NUP98 Motif at the Nuclear Pore Complex through Multiple Domains
J. Cell Biol.,
April 19, 1999;
145(2):
237 - 254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Persons, J. A. Allay, E. R. Allay, R. A. Ashmun, D. Orlic, S. M. Jane, J. M. Cunningham, and A. W. Nienhuis
Enforced Expression of the GATA-2 Transcription Factor Blocks Normal Hematopoiesis
Blood,
January 15, 1999;
93(2):
488 - 499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Erlich, S. R.P. Miranda, J. W.M. Visser, A. Dagan, S. Gatt, and E. H. Schuchman
Fluorescence-Based Selection of Gene-Corrected Hematopoietic Stem and Progenitor Cells From Acid Sphingomyelinase-Deficient Mice: Implications for Niemann-Pick Disease Gene Therapy and the Development of Improved Stem Cell Gene Transfer Procedures
Blood,
January 1, 1999;
93(1):
80 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Stevenson, S. Efstathiou, P. C. Doherty, and P. J. Lehner
Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses
PNAS,
July 18, 2000;
97(15):
8455 - 8460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Priller, D. A. Persons, F. F. Klett, G. Kempermann, G. W. Kreutzberg, and U. Dirnagl
Neogenesis of cerebellar Purkinje neurons from gene-marked bone marrow cells in vivo
J. Cell Biol.,
November 26, 2001;
155(5):
733 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract